menu
    • menu

    Company profile for Channel Therapeutics

    NEW Drugs in Dev: 2
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Channel Therapeutics is a clinical-stage biotechnology company dedicated to developing non-opioid, non-addictive therapeutics for pain management. Their primary focus is on selectively targeting the sodium ion channel NaV1.7, a pain receptor validated in human physiology. By modulating NaV1.7, Channel Therapeutics aims to prevent the transmission of pain perception to the central nervous system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Channel TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    685 US Highway One, North Brunswick, NJ 08902
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://channeltherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pelthos Doses First Patient in Phase 1b/2a CT2000 Eye Pain Trial
    Pelthos Doses First Patient in Phase 1b/2a CT2000 Eye Pain Trial

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265510/0/en/Pelthos-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-2a-Clinical-Trial-of-CT2000-in-Eye-Pain.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Pelthos Completes Merger, Closes $50.1M Private Placement
    Pelthos Completes Merger, Closes $50.1M Private Placement

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3109052/0/en/Pelthos-Therapeutics-Completes-Merger-with-Channel-Therapeutics-and-Closes-50-1-Million-Private-Placement.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share
    Ligand Completes Merger with Channel Therapeutics
    Ligand Completes Merger with Channel Therapeutics

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3109048/0/en/Ligand-Announces-Completion-of-Pelthos-Therapeutics-Merger-with-Channel-Therapeutics.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share
    Channel Therapeutics Announces Reverse Common Stock Split
    Channel Therapeutics Announces Reverse Common Stock Split

    27 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/27/3106598/0/en/Channel-Therapeutics-Announces-Reverse-Common-Stock-Split-in-Conjunction-with-the-Close-of-the-Merger-with-Pelthos-Therapeutics-and-Concurrent-50-1-Million-Private-Placement.html

    GLOBENEWSWIRE
    27 Jun 2025
    Share Share
    Channel Therapeutics Shows Eye Pain Relief via NaV1.7 Inhibitor
    Channel Therapeutics Shows Eye Pain Relief via NaV1.7 Inhibitor

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081100/0/en/Channel-Therapeutics-Announces-Positive-Efficacy-Results-for-the-Treatment-of-Eye-Pain-Using-its-NaV1-7-Inhibitor-in-Multiple-Preclinical-In-Vivo-Models.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Channel Therapeutics Announces 2024 Report for NYSE Compliance
    Channel Therapeutics Announces 2024 Report for NYSE Compliance

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072899/0/en/Channel-Therapeutics-Provides-Announcement-on-2024-Annual-Report-to-Comply-with-NYSE-American-Listing-Rules.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search